Danny Rischin, MD, on Adjuvant Cemiplimab for High-Risk CSCC
ASCO 2026
Danny Rischin, MD, of Peter MacCallum Cancer Centre, talks about data from the disease-free survival analyses of the C-POST study, which were conducted per high-risk criteria and start time after radiotherapy. C-POST evaluated adjuvant cemiplimab-rwlc for patients with high-risk cutaneous squamous cell carcinoma (CSCC) (Abstract 6083).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The C-POST trial is a phase 3 trial in patients with high-risk cutaneous squamous cell carcinoma. They compared adjuvant cemiplimab with placebo. In this trial, patients who had high-risk cutaneous SCC were randomized to either receive cemiplimab for 48 weeks or placebo. These patients had to have had surgery with complete macroscopic resection and have completed radiotherapy. This was a positive trial with clinically meaningful and statistically significant results: a hazard ratio of 0.32 and a P value of less than .001. So, a 68% reduction in the risk of disease recurrence or death, and this included a decrease in risk of locoregional recurrence and distant recurrences. At this ASCO meeting, we presented further analysis to better understand the benefits of cemiplimab as an adjuvant treatment in this population. In the C-POST trial, patients were selected based on high-risk criteria. These high-risk criteria could be nodal, such as having a lymph node that was greater than 2 cm with extranodal extension or more than 3 nodes, or several high-risk nonnodal criteria, such as in-transit metastases, T4 disease, perineural invasion, if there was involvement clinically or radiologically, or recurrent disease with other high-risk features. So what we wanted to see in these further analyses is whether all of these groups conveyed a disease-free benefit with cemiplimab compared with placebo. So we looked at all of these nodal and nonnodal criteria, and in fact, in every single group, there was similar disease-free benefit with cemiplimab versus placebo. The other thing that we looked at was the interval between completion of radiation and randomization. The protocol stipulated that patients had to start treatment or at least be randomized between 2 and 11 weeks after completing their radiotherapy. The median was 5.6 weeks. So we looked at the group that started within 2 to 6 weeks and the group that started in 6 to 11 weeks. And in fact, there was a similar disease-free benefit, irrespective of the interval since radiation. These analyses were conducted with updated follow-up, with a median follow-up of 30 months, and the overall disease-free benefit is still significant at 0.335. These results further reinforce that this benefit from adjuvant cemiplimab was seen in all the high-risk groups and irrespective of the interval from radiation. Further follow-up is ongoing of the C-POST trial, and longer-term follow-up and survival analysis will be presented at a later date.
The ASCO Post Staff
Lillian L. Siu, MD, of Princess Margaret Cancer Centre, discusses the clinical utility of liquid biopsy testing for common KRAS variants to facilitate matching patients with pancreatic ductal adenocarcinoma to appropriate early-phase trials (Abstract 3049).
The ASCO Post Staff
Noelle Cloven, MD, of Texas Oncology, discusses the actively recruiting RAINFOL-03 (ENGOT-EN-31/GOG-3128) study, a global, phase III, open-label, randomized study of rinatabart sesutecan vs investigator’s choice of chemotherapy in patients with endometrial cancer after receipt of platinum-based chemotherapy and PD-L1 inhibition (Abstract TPS5646).
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6 study of chemoimmunotherapy in HER2-negative advanced gastric/gastroesophageal junction (GEJ) cancer (Abstract 4006); and an investigational EP4 antagonist in combination with chemoimmunotherapy as a first-line strategy for HER2-negative gastric/GEJ cancer (Abstract 4007).
The ASCO Post Staff
Supriya Gupta, MD, of the University of Minnesota, presents data on azercabtagene zapreleucel, an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T-cell therapy, in combination with low-dose interleukin-2 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Abstract 7012).
The ASCO Post Staff
Robert C. Stein, PhD, MBBChir, FRCP, of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, discusses the first results from the phase III randomized OPTIMA trial, which is comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment with estrogen receptor (ER)-positive, HER2-negative early breast cancer (Abstract 500).